Research
Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands
-
* Corresponding author: Gijs AA Hubben g.hubben@rug.nl
1 University Center for Pharmacy, University of Groningen, The Netherlands
2 University Medical Center Groningen (UMCG), The Netherlands
3 Boehringer Ingelheim GmbH, Ingelheim, Germany
4 Boehringer Ingelheim BV, Alkmaar, The Netherlands
5 Pharmacy and Clinical Sciences, Medical University of South Carolina, Charleston, South Carolina, USA
6 Agenzia Regionale Socio Sanitaria del Veneto, Venice, Italy
Cost Effectiveness and Resource Allocation 2007, 5:15 doi:10.1186/1478-7547-5-15
Published: 22 November 2007